Glympse Bio, Inc.
- Headquarters
- CAMBRIDGE, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- glympsebio.com
- Total Funding
- $68.7M
- Last Round
- $46.7M Series BJun 2020
- Rounds
- 2
About
Glympse Bio developed engineered activity-based nanosensors (ABNs) to detect disease-associated protease activity in urine and blood, enabling non-invasive diagnostics for conditions including cancer and inflammatory diseases. The company merged with Sunbird Bio in 2023 to advance protein-based diagnostics for Alzheimer's and other neurological disorders.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Jun 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...